Dr. Rafat Abonour, MD
Claim this profileIndiana University/Melvin and Bren Simon Cancer Center
Studies Plasma Cell Neoplasm
Studies Multiple Myeloma
7 reported clinical trials
11 drugs studied
Area of expertise
1Plasma Cell Neoplasm
Stage I
Stage II
Stage III
2Multiple Myeloma
Stage I
Stage II
Stage III
Affiliated Hospitals
Clinical Trials Rafat Abonour, MD is currently running
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
GM T Cell Therapy Long-Term Follow-Up
for Cancer
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Recruiting1 award Phase 2 & 3
More about Rafat Abonour, MD
Clinical Trial Related7 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Rafat Abonour, MD has experience with
- Lenalidomide
- Dexamethasone
- Daratumumab
- Bortezomib
- Daratumumab And Hyaluronidase-fihj
- Carfilzomib
Breakdown of trials Rafat Abonour, MD has run
Plasma Cell Neoplasm
Multiple Myeloma
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Rafat Abonour, MD specialize in?
Is Rafat Abonour, MD currently recruiting for clinical trials?
Are there any treatments that Rafat Abonour, MD has studied deeply?
What is the best way to schedule an appointment with Rafat Abonour, MD?
What is the office address of Rafat Abonour, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.